Dr. Panteli Theocharous is global vice president, cell and gene therapy strategy lead at PPD. As a senior-level industry executive in prior CMO roles and a cancer immunotherapy expert, Dr. Theocharous has led multiple hematology/oncology assets in clinical development including innovative immuno-oncology technologies (1st generation clinical CAR-T cell applications in hematologic malignancies, and AAV gene-directed therapies in benign disorders) and successful life cycle management, MAA/NDA and HTA submissions. Dr. Theocharous’ background comprises a M.S. in applied clinical hematology from the University of London; and cancer medicine related higher degrees from the Royal Free and University College Medical School at the University of London, where he was clinical director for stem cell transplantation and cell and gene therapies.